ES2508566T3 - Cepas probióticas para su uso en mejorar el sistema nervioso entérico - Google Patents

Cepas probióticas para su uso en mejorar el sistema nervioso entérico Download PDF

Info

Publication number
ES2508566T3
ES2508566T3 ES11731504.4T ES11731504T ES2508566T3 ES 2508566 T3 ES2508566 T3 ES 2508566T3 ES 11731504 T ES11731504 T ES 11731504T ES 2508566 T3 ES2508566 T3 ES 2508566T3
Authority
ES
Spain
Prior art keywords
cncm
improving
strains
filed
vip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11731504.4T
Other languages
English (en)
Inventor
Sophie Legrain-Raspaud
Gianfranco Grompone
Sandrine Capronnier
Isabelle Chambaud
Tamara Smokvina
Marie-Christine Degivry
Biliana Lesic
Michel Neunlist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gervais Danone SA
Original Assignee
Gervais Danone SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gervais Danone SA filed Critical Gervais Danone SA
Application granted granted Critical
Publication of ES2508566T3 publication Critical patent/ES2508566T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cepa bacteriana seleccionada del grupo que consiste en: - DN_156_0032 (CNCM I-4321 presentada el 19 de mayo de 2010) - DN_121_0304 (CNCM I-4318 presentada el 19 de mayo de 2010), - DN_116_047 (CNCM I-4317 presentada el 19 de mayo de 2010) y - DN_154_0067 (CNCM I-4320 presentada el 19 de mayo de 2010)

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
5
10
15
20
25
30
35
E11731504
26-09-2014
las células se lavaron 3 veces en PBS, luego se permeabilizaron durante 30 min en PBS/NaN3 que contenía 0,5 % de Triton X-100 y 4 % de suero de caballo. Se diluyó anticuerpo primario : anti-enolasa específica de neurona de conejo (NSE) (1:2000; Biovalley, Francia) y anti-colina acetiltransferasa de conejo en PBS/NaN3, 0,5 % de Triton X100 y 4 % de suero de caballo y se incubaron durante la noche a temperatura ambiente. Después de la incubación con antisuero primario, las células se lavaron 3 veces con PBS y se incubaron durante 3 h con anti-IgG de conejo de burro conjugada con isotiocianato de fluoresceína (FITC) (1:200 Immunotech, Francia) y 7-amino-4-metil-cumarin-3acetato, respectivamente. Los especímenes se visualizaron bajo un microscopio de fluorescencia Olympus IX50 acoplado a cámara de vídeo blanca (Mod. 4910, Cohu Inc, Alemania) conectada a un ordenador macintosh mediante una tarjeta capturadora de fotogramas (Scion Imagen, SL Microtest).
Mediciones de VIP:
Para la determinación de VIP, células neuronales se recogieron de las placas de 12 pocillos, las proteínas se extrajeron usando tampón de lisis RIPA (Millipore, Francia) que contiene mezcla de inhibidores de proteasas (Roche Diagnostics, Francia) y se midieron los niveles de VIP por ELISA (Bachem, Alemania).
Resultados
La respuesta diferencial de neuronas entéricas primarias en marcadores de VIP y ChAT tras la interacción de algunas de las 102 cepas probióticas que incluyen bacterias ácido lácticas y bifidobacterias se muestra en la Tabla
1. Solo se muestran algunas cepas que pertenecen al grupo A3) o B3) o C3). Adicionalmente se menciona que se mostró que 26 cepas no tuvieron efecto significativo sobre VIP y ChAT (incluyendo las cepas Bifidobacterium longum NCC 2705 (CNCM I-2618), Lactobacillus rhamnosus GG (ATCC 53103) y Lactobacillus casei Shirota), se mostró que 11 cepas que pertenecen al grupo C2) redujeron tanto VIP como ChAT (incluyendo la cepa Bifidobacterium longum W11 de Alfa-Wass (LMG P-21586)), 10 cepas disminuyeron VIP y no tuvieron efecto sobre ChAT (incluyendo las cepas de punto de referencia Bifidobacterium infantis UCC 3564, Bifidobacterium longum Bb536, Bifidobacterium animalis spp lactis Bbl2 (DSM 15954) y Bifidobacterium animalis spp lactis Bi-07 (ATCC SD5220) y 41 cepas que pertenecen al grupo C3) disminuyeron ChAT y no tuvieron efecto sobre VIP que incluye las cepas Lactobacillus johnsonii La1 (CNCM I-1225), Lactobacillus plantarum 299v (DSM 9843), Lactobacillus reuteri SD 2122 (ATCC 55730)).
Tabla 1: Efecto de la incubación con bacterias ácido lácticas y bifidobacterias sobre los niveles de VIP y de ChAT en un modelo de co-cultivo con monocapa de células epiteliales y células primarias del SNE.
VIP
ChAT
Grupo
Número DN de especies (número de CNCM) Diferencia estimada* frente al control valor de p Media empírica Diferencia estimada frente al control valor de p Media empírica
1
DN_154_0067 (CNCM I-4320 presentada el 19 de mayo de 2010) Bifidobacterium bifidum -0,0097 0,9 0,0790 0,2709 0,09 0,1796
1
DN_116_0047 (CNCM I-4317 presentada el 19 de mayo de 2010) Lactobacillus rhamnosus -0,0389 0,7 0,0397 0,3151 0,10 0,2535
1
DN_119_0118 (CNCM I-4279 presentada el 25 de febrero de 2010) Lactobacillus acidophillus -0,1329 0,09 -0,2221 0,2847 0,02 0,2796
2
DN_173_010 (CNCM I-2494 presentada el 20 de junio de 2000) Bifidobacterium lactis 0,2345 0,01 0,2001 -0,2615 0,05 -0,0825
2
DN_156_0032 (CNCM I-4321 presentada el 19 de mayo de 2010) Bifidobacterium breve 0,2248 0,01 0,2020 -0,5450 0,00 -0,5723
2
DN_156_007 (CNCM I-2219 presentada el 31 de mayo de 1999) Bifidobacterium breve 0,2715 0,02 0,3552 -0,3632 0,01 -0,1281
2
DN_121_0304 (CNCM I-4318 presentada el 19 de mayo de 2010) Lactobacillus plantarum 0,5976 0,00 0,6813 -0,6269 0,00 -0,3918
* Los valores se facilitan como una diferencia en comparación con el control, al que no se añadieron cepas bacterianas.
Aunque la cepa DN_119_0118 (CNCM I-4279 presentada el 25 de febrero de 2010) disminuye los niveles de VIP, resultó con un modelo de TEER (Hirotani y col., 2008, Yakugaku Zasshi Sep; 128(9):1363-8) que la incubación con la cepa durante 4 ó 6 h no redujo significativamente los valores de TEER, incluso en presencia de lesión frente al
12
imagen11

Claims (1)

  1. imagen1
ES11731504.4T 2010-05-28 2011-05-27 Cepas probióticas para su uso en mejorar el sistema nervioso entérico Active ES2508566T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2010/001534 WO2011148219A1 (en) 2010-05-28 2010-05-28 Probiotic strains for use in improving the enteric nervous system
WOPCT/IB2010/001534 2010-05-28
PCT/IB2011/052344 WO2011148355A1 (en) 2010-05-28 2011-05-27 Probiotic strains for use in improving the enteric nervous system

Publications (1)

Publication Number Publication Date
ES2508566T3 true ES2508566T3 (es) 2014-10-16

Family

ID=43302705

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11731504.4T Active ES2508566T3 (es) 2010-05-28 2011-05-27 Cepas probióticas para su uso en mejorar el sistema nervioso entérico
ES14173452T Active ES2744274T3 (es) 2010-05-28 2011-05-27 Cepas probióticas para usar en la mejora del sistema nervioso entérico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14173452T Active ES2744274T3 (es) 2010-05-28 2011-05-27 Cepas probióticas para usar en la mejora del sistema nervioso entérico

Country Status (14)

Country Link
US (2) US9198940B2 (es)
EP (2) EP2857027B1 (es)
JP (1) JP5923492B2 (es)
KR (1) KR101779832B1 (es)
CN (1) CN103209698B (es)
BR (1) BR112012030359B1 (es)
CA (1) CA2800768C (es)
EA (1) EA028015B1 (es)
ES (2) ES2508566T3 (es)
MX (1) MX345063B (es)
PL (1) PL2575837T3 (es)
PT (1) PT2575837E (es)
WO (2) WO2011148219A1 (es)
ZA (1) ZA201208977B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2609813A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system
UA118339C2 (uk) * 2012-09-03 2019-01-10 Біогайа Аб Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)
RU2015122728A (ru) 2012-11-12 2017-01-10 Компани Жервэ Данон Штамм lactobacillus rhamnosus для уменьшения накопления жира в организме
WO2014096901A1 (en) * 2012-12-18 2014-06-26 Compagnie Gervais Danone Strain of bifidobacterium animalis ssp. animalis
FR3004621B1 (fr) 2013-04-19 2015-05-15 Gervais Danone Sa Souche de lactobacillus rhamnosus regulatrice du metabolisme lipidique
CN103898007B (zh) * 2014-02-21 2016-08-17 刘洛贤 一株有活性的双歧杆菌菌株
JP6402016B2 (ja) * 2014-12-10 2018-10-10 国立大学法人岐阜大学 神経機能改善剤
CN107847483A (zh) * 2015-04-30 2018-03-27 益生菌股份公司 具有特定治疗活性的抗生素与具有相同治疗适应证的具有不可转移抗生素抗性的乳酸杆菌和/或双歧杆菌同时联用的应用
US9730969B2 (en) 2015-11-06 2017-08-15 Mead Johnson Nutrition Company Nutritional compositions for promoting gut barrier function and ameliorating visceral pain
CA3063669C (en) * 2017-09-29 2023-08-01 University-Industry Cooperation Group Of Kyung Hee University Lactobacillus reuteri strain and uses thereof
CN108753670A (zh) * 2018-05-28 2018-11-06 西北工业大学 多功能复合微生态制剂纳米硒-重组表达血管活性肠肽-乳酸乳球菌及制备方法
KR102238519B1 (ko) * 2018-12-28 2021-04-13 (주)메디톡스 외래 단백질을 발현하는 미생물, 및 그의 용도
KR102635553B1 (ko) * 2018-12-28 2024-02-13 주식회사 리비옴 외래 단백질을 발현하는 미생물, 및 그의 용도
CA3161418C (en) * 2019-12-17 2024-05-21 Noelle Marie PATNO Multi-strain probiotic composition and its use
KR20210129516A (ko) 2020-04-20 2021-10-28 주식회사 리비옴 혈관 작동성 장 펩티드를 발현하는 미생물, 및 그의 용도
KR102527954B1 (ko) * 2021-03-29 2023-05-03 주식회사 리비옴 외래 단백질을 발현하는 미생물, 및 그의 용도
CN113248520A (zh) * 2021-04-07 2021-08-13 浙江华显光电科技有限公司 一种有机化合物及使用该化合物的有机发光器件
WO2024080918A1 (en) * 2022-10-13 2024-04-18 Baylor College Of Medicine Secretin inducing bacteria

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07173188A (ja) * 1993-12-17 1995-07-11 Tsumura & Co 新規アリソールおよびアリソール類を有効成分とする脳機能改善剤
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
FR2795917B1 (fr) 1999-07-06 2001-08-31 Gervais Danone Sa Procede de preparation d'un produit lacte immunostimulant et ses applications
FR2811333B1 (fr) 2000-07-04 2003-01-10 Gervais Danone Sa Microorganismes ayant une action modulatrice de la glycosylation de surface des cellules intestinales et methode de selection desdits microorganismes
PE20030284A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
FR2875406B1 (fr) 2004-09-21 2007-01-05 Danisco Souche de lactobacillus acidophilus ayant des proprietes analgesiques au niveau du systeme gastro-intestinal
ITMI20042189A1 (it) * 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
AU2006296837B2 (en) 2005-09-28 2012-12-13 Nordic Rebalance A/S Treatment of IBD and IBS using both probiotic bacteria and fermented cereal as treatment effectors
US20090311227A1 (en) 2006-05-12 2009-12-17 Danisco A/S Composition
CN101095698B (zh) * 2006-06-26 2010-12-01 青岛东海药业有限公司 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途
WO2008064489A1 (en) 2006-12-01 2008-06-05 Mcmaster University Probiotics to inhibit inflammation
FR2921795B1 (fr) * 2007-10-03 2011-04-29 Gervais Danone Sa Utilisation d'une souche de bifidobacterium,pour la preparation d'une composition destinee a la prevention et/ou au traitement de manifestations de type allergique
EP2072053B1 (en) 2007-12-21 2012-11-07 Compagnie Gervais Danone Method for decreasing abdominal girth by administering a bifidobacterium bacteria
WO2010008272A1 (en) * 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
EA021890B1 (ru) * 2009-11-02 2015-09-30 Компани Жервэ Данон Способ предотвращения и/или лечения болезни воспаленного кишечника, язвенного колита и болезни крона
WO2011148220A1 (en) * 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving transepithelial resistance

Also Published As

Publication number Publication date
US20130195822A1 (en) 2013-08-01
EP2857027A1 (en) 2015-04-08
EP2575837A1 (en) 2013-04-10
KR101779832B1 (ko) 2017-09-19
MX2012013834A (es) 2013-04-08
KR20140000620A (ko) 2014-01-03
US9198940B2 (en) 2015-12-01
ES2744274T3 (es) 2020-02-24
CA2800768C (en) 2020-07-21
WO2011148355A1 (en) 2011-12-01
CN103209698B (zh) 2015-09-02
BR112012030359B1 (pt) 2020-05-05
MX345063B (es) 2017-01-16
ZA201208977B (en) 2014-04-30
PL2575837T3 (pl) 2015-03-31
JP2013528053A (ja) 2013-07-08
PT2575837E (pt) 2014-10-01
BR112012030359A2 (pt) 2016-08-09
JP5923492B2 (ja) 2016-05-24
CN103209698A (zh) 2013-07-17
EP2857027B1 (en) 2019-06-12
CA2800768A1 (en) 2011-12-01
EP2575837B1 (en) 2014-06-25
WO2011148219A1 (en) 2011-12-01
US20160045557A1 (en) 2016-02-18
EA028015B1 (ru) 2017-09-29
EA201291441A1 (ru) 2013-05-30

Similar Documents

Publication Publication Date Title
ES2508566T3 (es) Cepas probióticas para su uso en mejorar el sistema nervioso entérico
Lebeer et al. Identification of probiotic effector molecules: present state and future perspectives
Adak et al. An insight into gut microbiota and its functionalities
Ranadheera et al. Effect of dairy probiotic combinations on in vitro gastrointestinal tolerance, intestinal epithelial cell adhesion and cytokine secretion
ES2636944T3 (es) Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
Lim et al. Screening and characterization of probiotic lactic acid bacteria isolated from Korean fermented foods
JP2024003162A (ja) クロストリジウム・ディフィシル感染症の治療における新たな使用
Ishibashi et al. Probiotics and safety
Fernandez et al. Growth, acid production and bacteriocin production by probiotic candidates under simulated colonic conditions
Núñez et al. Evaluation of immune response, microbiota, and blood markers after probiotic bacteria administration in obese mice induced by a high-fat diet
ES2616334T3 (es) Probióticos, IgA secretora e infección
RU2009147036A (ru) Пробиотики в пред- и/или послеоперационный период
EP2548563B1 (en) Anti-allergic composition comprising lactobacillus crispatus kt-11
Raveschot et al. Probiotic Lactobacillus strains from Mongolia improve calcium transport and uptake by intestinal cells in vitro
JP2010527343A5 (es)
Ekmekciu et al. Fecal microbiota transplantation, commensal Escherichia coli and Lactobacillus johnsonii strains differentially restore intestinal and systemic adaptive immune cell populations following broad-spectrum antibiotic treatment
RU2011150201A (ru) Кратковременная высокотемпературная обработка для микробных препаратов с противовоспалительными свойствами
JP2014518897A5 (es)
CN110114073A (zh) 憩室形成和憩室病的治疗中使用的益生菌
Divya et al. Encapsulated Lactococcus lactis with enhanced gastrointestinal survival for the development of folate enriched functional foods
Zivkovic et al. Capability of exopolysaccharide-producing Lactobacillus paraplantarum BGCG11 and its non-producing isogenic strain NB1, to counteract the effect of enteropathogens upon the epithelial cell line HT29-MTX
Scully et al. Bifidobacterium infantis suppression of Peyer’s patch MIP-1α and MIP-1β secretion during Salmonella infection correlates with increased local CD4+ CD25+ T cell numbers
Heydarian et al. A comparison between traditional yogurt and probiotic yogurt in non-inflammatory acute gastroenteritis
Burns et al. Impact of bile salt adaptation of Lactobacillus delbrueckii subsp. lactis 200 on its interaction capacity with the gut
HRP20130487A2 (hr) Formulacija probiotika s apigeninom i ekstraktom paprene metvice